UNIVERSAL HEALTH SERVICES INC
UHS$14.26B
Large CapNASDAQBiotechnology🇺🇸North America99.3K employees
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
UHS News
Catalyst Timeline
1 upcoming, 0 past
EarningsNext
INC Reports Financial Results
Apr 28, 2026Confirmed
Filed: 2026-04-28 AccNo: 0001193125-26-183643 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
SourceDrug Pipeline
Picosulfate sodium, magnesium oxide, citric acid
Bowel Preparation Before Colonoscopy
Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
Bowel Preparation
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Picosulfate sodium, magnesium oxide, citric acid | Phase 3 | Bowel Preparation Before Colonoscopy | - | - |
Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) | Phase 3 | Bowel Preparation | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply